By continuing on our website, you agree to our use of the cookie for statistical and personalization purpose.
Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
Data from 2015 (or nearest year available). Data reflect age- and sex- standardized, hospital admission-based diabetes lower extremity amputation rates for adults aged 15 years and older.